{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:30:50Z","timestamp":1786681850134,"version":"build-2736575974"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Targeted therapy and immune checkpoint inhibition have improved the treatment of non-small cell lung cancer (NSCLC); however, it remains one of the leading causes of cancer-related mortality worldwide. While all these therapeutic strategies have yielded clinical benefit in specific patient groups, resistance and tumor heterogeneity, short-term responses, and immune evasion remain current challenges in long-term therapeutic success. These constraints have led to the exploration of new precision immuno-oncology approaches for more specific targeting more efficient stimulation of antitumor immune responses and overcoming resistance mechanisms. Among these new modalities, antibody-drug conjugates (ADCs), therapeutic cancer vaccines, and adoptive cellular therapies are significantly changing the systemic treatment paradigm in NSCLC. Simultaneously, advances in neoantigen discovery, mRNA vaccine technology, and personalized vaccine design have renewed interest in therapeutic cancer vaccines for generating durable antitumor immune responses. In parallel, adoptive cellular immunotherapies, such as chimeric antigen receptor (CAR)-T cells, natural killer (NK)-cells, and tumor-infiltrating lymphocytes (TILs) are growing as effective approaches to improve immune-mediated tumor eradication in NSCLC. This manuscript summarizes the recent developments of these next-generation precision immuno-oncology platforms, highlighting their working mechanisms, progress in translation, and clinical use. It also explores strategies for combinational therapy, predictive biomarkers, inhibitors of tumor microenvironment modulation, and mechanisms of resistance in the context of therapeutic efficacy and patient selection. Collectively, these developing immunotherapeutic platforms as a whole constitute a brighter paradigm for more personalized and effective systemic treatment approaches in NSCLC.<\/jats:p>","DOI":"10.3389\/fonc.2026.1904492","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:04Z","timestamp":1786681384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision immuno-oncology in NSCLC: integrating ADCs, therapeutic vaccines, and adoptive cell therapies for next-generation systemic treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Pankaj","family":"Garg","sequence":"first","affiliation":[{"name":"Department of Chemistry, GLA University","place":["Mathura, Uttar Pradesh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutic Research, Beckman Research Institute of City of Hope","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14196960","article-title":"Update on the treatment of non-small cell lung carcinoma (NSCLC)","volume":"14","author":"Kariri","year":"2025","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.20517\/cdr.2025.122","article-title":"New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer","volume":"8","author":"Long","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"20251179","DOI":"10.1515\/biol-2025-1179","article-title":"Advances in cancer immunotherapy and future directions in personalized medicine","volume":"20","author":"Wang","year":"2025","journal-title":"Open Life Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116498","article-title":"Gynecological cancer tumor microenvironment: Unveiling cellular complexity and therapeutic potential","volume":"229","author":"Garg","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26167958","article-title":"Research progress of platinum-based complexes in lung cancer treatment: Mechanisms, applications, and challenges","volume":"26","author":"Liang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules31071195","article-title":"Molecularly targeted therapies in oncology: Mechanisms, resistance, and combination strategies","volume":"31","author":"Giercuszkiewicz-Ha\u015bnik","year":"2026","journal-title":"Molecules"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216537","article-title":"Next-generation immunotherapy: Advancing clinical applications in cancer treatment","volume":"13","author":"Garg","year":"2024","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1250975","article-title":"Editorial: Combinational immunotherapy of cancer: Novel targets, mechanisms, and strategies","volume":"14","author":"Nan","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules31071180","article-title":"Antibody-drug conjugates (ADCs): A review of structural design, technological evolution, and future perspectives","volume":"31","author":"Wu","year":"2026","journal-title":"Molecules (Basel Switzerland)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: A comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1729-8","article-title":"Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates","volume":"32","author":"Xu","year":"2015","journal-title":"Pharm Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.12.001","article-title":"Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping","volume":"23","author":"Khera","year":"2021","journal-title":"Neoplasia (New York NY)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1787148","article-title":"Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer","volume":"17","author":"Guo","year":"2026","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1332057","article-title":"Targeting HER3 to overcome EGFR TKI resistance in NSCLC","volume":"14","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/biom16050677","article-title":"Antibody\u2013drug conjugates beyond HER2 in non-small cell lung cancer (NSCLC): Mechanisms, emerging targets, and future directions","volume":"16","author":"Ismail","year":"2026","journal-title":"Biomolecules"},{"key":"B19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of Patritumab Deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.629266","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70178","article-title":"Treatment-related adverse events of antibody-drug conjugate monotherapy in non-small cell lung cancer: A systematic review and meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Thorac Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17080967","article-title":"A dual-payload bispecific ADC improved potency and efficacy over single-payload bispecific ADCs","volume":"17","author":"Wilski","year":"2025","journal-title":"Pharmaceutics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105068","article-title":"The role of therapeutic cancer vaccines in the modern immunotherapy era: State of the art with recent progress and future challenges","volume":"217","author":"Rota","year":"2026","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: Target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol Aspects Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040337","article-title":"The application of dendritic cells vaccines in tumor therapy and their combination with biomimetic nanoparticles","volume":"13","author":"Zhu","year":"2025","journal-title":"Vaccines"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2026.189577","article-title":"mRNA-based cancer vaccines: A new frontier in personalized immunotherapy","volume":"1881","author":"Garg","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-026-01778-7","article-title":"Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: Evidence and future perspectives","volume":"19","author":"Tang","year":"2026","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010144","article-title":"Advances in neoantigen-based cancer vaccines","volume":"18","author":"Wu","year":"2026","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: Advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transd Targ Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125503","article-title":"Understanding the immune system\u2019s intricate balance: Activation, tolerance, and self-protection","volume":"26","author":"Chen","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2025.26.8.2741","article-title":"Personalized cancer vaccines in combination therapies: Current status and future prospects","volume":"26","author":"Rukhayya","year":"2025","journal-title":"Asian Pac J Cancer Prev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immunotherapeutics: Platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20210058","article-title":"Adoptive cell therapy for cancer treatment","volume":"3","author":"Du","year":"2023","journal-title":"Explor (Beijing China)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.115012","article-title":"Engineering immune cells for next-generation therapies","volume":"395","author":"Han","year":"2026","journal-title":"J Controlled Rel"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1186\/s12967-025-07259-8","article-title":"Innovative gene engineering strategies to address tumor antigen escape in cell therapy","volume":"23","author":"Chen","year":"2025","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/pharmacia.72.e173384","article-title":"Chimeric antigen receptor (CAR) T cell therapy: Current landscape, challenges, and future horizons in hematologic and solid tumors","volume":"72","author":"Al-Hussaniy","year":"2025","journal-title":"Pharmacia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45110566","article-title":"Advances in CAR T cell therapy for non-small cell lung cancer","volume":"45","author":"Ma","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK cell therapy: Promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: From natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01112-2","article-title":"Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer","volume":"48","author":"Tovar Manzano","year":"2025","journal-title":"Cell Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00262-024-03793-4","article-title":"Recent clinical researches and technological development in TIL therapy","volume":"73","author":"Matsueda","year":"2024","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121945","article-title":"Next-generation CAR-T and TCR-T cell therapies for solid tumors: Innovations, challenges, and global development trends","volume":"17","author":"Sanomachi","year":"2025","journal-title":"Cancers"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13090898","article-title":"TCR-T cell recognition of an NY-ESO-1 epitope presented by HLA-A2 supertype: Implications for cancer immunotherapy","volume":"13","author":"Lin","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665488","article-title":"Recent advances in adoptive cell therapy for cancer immunotherapy","volume":"16","author":"Qian","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxford Open Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.05.019","article-title":"Next-generation CAR-T therapies: From personalized anticancer drugs to broadly applicable disease-modifying treatments","author":"Wen","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189233","article-title":"Unveiling the potential of gene editing techniques in revolutionizing cancer treatment: A comprehensive overview","volume":"1880","author":"Garg","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/imcb.70114","article-title":"Defining the tumor microenvironment of non-small cell lung cancer","volume":"104","author":"Embaye","year":"2026","journal-title":"Immunol Cell Biol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/bs.pmbts.2022.10.002","article-title":"Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity","volume":"194","author":"Singh","year":"2023","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"5","author":"Xiang","year":"2024","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06538-0","article-title":"Metabolic reprogramming and therapeutic targeting in non-small cell lung cancer: emerging insights beyond the Warburg effect","volume":"15","author":"Cai","year":"2025","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fimmu.2025.1728163","article-title":"Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-026-03656-z","article-title":"Rewiring tumor cytokine networks to enhance immune checkpoint blockade: Mechanisms, engineering, and clinical translation","volume":"45","author":"Wang","year":"2026","journal-title":"J Exp Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S567238","article-title":"Emerging predictive biomarkers of immunotherapy sensitivity in patients with non-small cell lung cancer","volume":"15","author":"Gariazzo","year":"2026","journal-title":"ImmunoTarg Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01892-9","article-title":"TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses","volume":"26","author":"Das","year":"2026","journal-title":"Clin Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216365","article-title":"Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration","volume":"577","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf331","article-title":"Antibody drugs conjugates in non-small cell lung cancer: current status and challenges","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.62347\/BKIS3836","article-title":"TROP2-targeted molecular imaging: A promising tool for precision oncology","volume":"15","author":"Ye","year":"2025","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1554871","article-title":"Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071771","article-title":"Evaluation of the TCR repertoire as a predictive and prognostic biomarker in cancer: diversity or clonality","volume":"14","author":"Aran","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-026-02821-4","article-title":"Artificial intelligence and machine learning in non-small cell lung cancer: the current state of the science on multi-omic applications","volume":"26","author":"Nistala","year":"2026","journal-title":"BMC Med Res Methodol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1732079","article-title":"Artificial intelligence-enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbaf017","article-title":"Reprogramming the tumor microenvironment: synergistic mechanisms of antibody\u2013drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antibody Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-26-517110","article-title":"Advancing antibody-drug conjugates: Current perspectives and future directions","volume":"46","author":"Etessami","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jrras.2026.102253","article-title":"Radiotherapy as an immunomodulator in cancer: Synergy with immunotherapy and roadmap for optimization","volume":"19","author":"Zhao","year":"2026","journal-title":"J Radiat Res Appl Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transd Targ Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3632","article-title":"The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer","volume":"49","author":"Zhang","year":"2016","journal-title":"Int J Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03139-6","article-title":"Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies","volume":"133","author":"Rocca","year":"2025","journal-title":"Br J Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144189","article-title":"Advances in non-small cell lung cancer: current insights and future directions","volume":"13","author":"Garg","year":"2024","journal-title":"J Clin Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40137-018-0202-0","article-title":"Multimodality treatment of advanced non-small cell lung cancer: where are we with the evidence","volume":"6","author":"Jones","year":"2018","journal-title":"Curr Surg Rep"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100071","article-title":"Multimodal predictors for precision immunotherapy","volume":"14","author":"Roelofsen","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12967-025-06589-x","article-title":"Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/actr-24-206","article-title":"Patritumab deruxtecan: Advancing the treatment landscape for EGFR-resistant non-small cell lung cancer","volume":"3","author":"Parisi","year":"2025","journal-title":"AME Clin Trials Rev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35088","article-title":"The current therapeutic cancer vaccines landscape in non-small cell lung cancer","volume":"155","author":"Chen","year":"2024","journal-title":"Int J Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s13402-026-01199-1","article-title":"Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy","volume":"49","author":"Li","year":"2026","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102662","article-title":"CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management","volume":"64","author":"Liu","year":"2026","journal-title":"Transl Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06538-0","article-title":"Expanding the frontier of CAR therapy: comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches","volume":"104","author":"Zhang","year":"2025","journal-title":"Ann Hematol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtadv.2026.100808","article-title":"Engineering the future of precision cancer immunotherapy: Integrating neoantigen biology, engineered delivery platforms, and clinical translation","volume":"30","author":"Khan","year":"2026","journal-title":"Mater Today Adv"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050378","article-title":"Management and prevention of cellular-therapy-related toxicity: early and late complications","volume":"30","author":"Mucha","year":"2023","journal-title":"Curr Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14228021","article-title":"Redefining the diagnostic and therapeutic landscape of non-small cell lung cancer in the era of precision medicine","volume":"14","author":"Khan","year":"2025","journal-title":"J Clin Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41698-025-01159-2","article-title":"Leveraging artificial intelligence in antibody-drug conjugate development: From target identification to clinical translation in oncology","volume":"9","author":"Lu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01153-x","article-title":"Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy","volume":"21","author":"Zhu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.crbiot.2025.100356","article-title":"CRISPR-Cas12 in immunotherapy and beyond: Advances and challenges","volume":"11","author":"Zarei Taher","year":"2026","journal-title":"Curr Res Biotechnol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-026-01791-w","article-title":"Current and future immunotherapies for NSCLC","volume":"19","author":"Zhou","year":"2026","journal-title":"J Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432526","article-title":"Beyond chemoimmunotherapy in advanced non\u2013small cell lung cancer: New frontiers, new challenges","volume":"44","author":"Mountzios","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B89","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10238-026-02107-5","article-title":"Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases","volume":"26","author":"Alshorman","year":"2026","journal-title":"Clin Exp Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1728163","article-title":"Lung cancer immunotherapy in 2025: Where we stand and what comes next","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1904492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:06Z","timestamp":1786681386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1904492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":90,"alternative-id":["10.3389\/fonc.2026.1904492"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1904492","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1904492"}}